ST. LOUIS--(BUSINESS WIRE)--Mallinckrodt, the pharmaceuticals business of Covidien (NYSE: COV), a leading global provider of healthcare products, today announced the launch of its morphine sulfate oral solution for the relief of moderate-to-severe acute and chronic pain in opioid-tolerant patients. The solution is the first generic morphine oral solution to be approved by the U.S. Food and Drug Administration (FDA), and it is available in 100 milligrams per 5 mL (20 milligrams per 1 mL).
